Zobrazeno 1 - 10
of 46
pro vyhledávání: '"Michihiro Uchiyama"'
Autor:
Antonio Maria Risitano, Alexander Röth, Austin Kulasekararaj, Phillip Scheinberg, Yasutaka Ueda, Carlos de Castro, Eros DI Bona, Morag Griffin, Saskia Langemeijer, Hubert Schrezenmeier, Wilma Barcellini, Vitor Aq Mauad, Jens Panse, Philippe Schafhausen, Suzanne Tavitian, Eloise Beggiato, Anna Gaya, Wei-Han Huang, Toshio Kitawaki, Abdullah Kutlar, Jaroslaw P Maciejewski, Rosario Notaro, Vinod Pullarkat, Jörg Schubert, Louis Terriou, Michihiro Uchiyama, Flore Sicre de Fontbrune, Luana Marano, Ferras Alashkar, Shreyans Gandhi, Cécile Kerloëguen, Rakesh Kumar, Christine Thorburn, Samopriyo Maitra, Marion Dahlke, Régis Peffault de Latour
Publikováno v:
HemaSphere, Vol 7, p e29006c9 (2023)
Externí odkaz:
https://doaj.org/article/efa1233f722549f49a84c98218df9720
Autor:
Toru Kiguchi, Yasushi Hiramatsu, Shuichi Ota, Michihiro Uchiyama, Moe Matsuo, Miyu Okamura, Shimpei Morimoto, Yoshinori Tanizawa, Masaomi Tajimi, Payakachat, Nalin
Publikováno v:
Journal of Clinical & Experimental Hematopathology; 2024, Vol. 64 Issue 2, p119-128, 10p
Autor:
Kazutaka Sunami, Shin‐ichi Fuchida, Kenshi Suzuki, Masaki Ri, Morio Matsumoto, Chihiro Shimazaki, Hideki Asaoku, Hirohiko Shibayama, Kenichi Ishizawa, Hiroyuki Takamatsu, Takashi Ikeda, Dai Maruyama, Kazunori Imada, Michihiro Uchiyama, Toru Kiguchi, Satoshi Iyama, Hirokazu Murakami, Reiko Onishi, Keisuke Tada, Shinsuke Iida
Publikováno v:
Hematological oncologyREFERENCES.
The primary analysis of the phase 1/2 ISLANDs study in Japanese individuals with relapsed/refractory multiple myeloma (RRMM) showed that isatuximab monotherapy was well tolerated and effective, even in participants with high-risk cytogenetic abnormal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4f7e61ae3682a73047a4b7ac6fef1737
https://pubmed.ncbi.nlm.nih.gov/36433829
https://pubmed.ncbi.nlm.nih.gov/36433829
Autor:
Tadao Ishida, Shigeki Ito, Junji Tanaka, Michihiro Uchiyama, Yawara Kawano, Philippe Moreau, Thomas Martin, Marie-Laure Risse, Keisuke Tada, Kenshi Suzuki, Kenichi Ishizawa
Publikováno v:
Japanese journal of clinical oncology. 52(12)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ee3b9d00f02f035a23f03265207a3262
https://pubmed.ncbi.nlm.nih.gov/36073950
https://pubmed.ncbi.nlm.nih.gov/36073950
Autor:
Takashi Ikeda, Kenichi Ishizawa, Chihiro Shimazaki, Keishiro Takahashi, Hirohiko Shibayama, Hitomi Kaneko, Hirokazu Murakami, Dai Maruyama, Michihiro Uchiyama, Hélène Guillemin-Paveau, Toru Kiguchi, Kazutaka Sunami, Sandrine Macé, Masaki Ri, Hideki Asaoku, Hiroyuki Takamatsu, Morio Matsumoto, Keisuke Tada, Kenshi Suzuki, Satoshi Iyama, Shinsuke Iida
Publikováno v:
Cancer Science
Isatuximab, an anti‐CD38 monoclonal antibody, targets cells that strongly express CD38 including malignant plasma cells. This open‐label, single‐arm, multicenter, phase 1/2 trial investigated the tolerability/safety and efficacy of isatuximab m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d885dc89d6541068d90c08ae5e406565
https://doi.org/10.1111/cas.14657
https://doi.org/10.1111/cas.14657
Autor:
Tanaka Junji, Sung-Hyun Kim, Jin Seok Kim, Youngil Koh, Kenichi Ishizawa, Thomas G. Martin, Yvonne Dong, Marie-Laure Risse, Philippe Moreau, Kenshi Suzuki, Chang-Ki Min, Michihiro Uchiyama, Kihyun Kim, Shigeki Ito, Yawara Kawano
Publikováno v:
International journal of hematology. 116(4)
e20015 Background: The Phase 3 IKEMA study (NCT03275285) demonstrated that isatuximab (Isa) plus carfilzomib and dexamethasone (Kd) significantly improved progression-free survival (PFS) compared with Kd in patients (pts) with relapsed multiple myelo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b9e7defc38d265c0b09297563caf0bdd
https://pubmed.ncbi.nlm.nih.gov/35578151
https://pubmed.ncbi.nlm.nih.gov/35578151
Autor:
Kazutaka Sunami, Takashi Ikeda, Shang-Yi Huang, Ming-Chung Wang, Youngil Koh, Chang Ki Min, Su-Peng Yeh, Morio Matsumoto, Michihiro Uchiyama, Satoshi Iyama, Chihiro Shimazaki, Jae Hoon Lee, Kihyun Kim, Hitomi Kaneko, Jin Seok Kim, Tung-Liang Lin, Frank Campana, Keisuke Tada, Shinsuke Iida, Kenshi Suzuki
Publikováno v:
Clinical lymphoma, myelomaleukemia. 22(8)
In the pivotal phase III, randomized, multicenter ICARIA-MM study (NCT02990338), isatuximab plus pomalidomide and dexamethasone (Isa-Pd) improved progression-free survival and overall response rate versus pomalidomide and dexamethasone (Pd) in the ov
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ac8fbd48e8b2907d257c503e37d0402
https://pubmed.ncbi.nlm.nih.gov/35641409
https://pubmed.ncbi.nlm.nih.gov/35641409
Autor:
Sunghyun Kim, Chang-Ki Min, Michihiro Uchiyama, Kenichi Ishizawa, Junji Tanaka, Yvonne Dong, Jin Seok Kim, Ki-Hyun Kim, Shigeki Ito, Youngil Koh, Thomas Martin, Yawara Kawano, Marie-Laure Risse, Philippe Moreau, Kenshi Suzuki
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:S146-S147
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8c39785ce17676c6f14674be232bdc1d
https://doi.org/10.1016/s2152-2650(21)02325-9
https://doi.org/10.1016/s2152-2650(21)02325-9
Autor:
Junichi Nishimura, Yuzuru Kanakura, Jun Yokosawa, Hideyoshi Noji, Shinichiro Okamoto, Rasha Aguzzi, Ken Ishiyama, Shinji Nakao, Yasuo Mori, Kensuke Usuki, Michihiro Uchiyama, Yuji Yonemura, Shin ichiro Fujiwara, Scott T. Rottinghaus, Masaya Okada, Takayuki Ikezoe, Tetsuya Fukuda
Publikováno v:
International journal of hematology. 112(4)
Ravulizumab demonstrated noninferior efficacy and comparable safety to eculizumab in two open-label, phase 3 studies in patients with paroxysmal nocturnal hemoglobinuria (PNH) who complement inhibitor-naive (Study 301) or were previously treated with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7daf6320e741a9c62b6a94f58e209814
https://pubmed.ncbi.nlm.nih.gov/32869125
https://pubmed.ncbi.nlm.nih.gov/32869125
Autor:
Junichi Sakamoto, Noriyoshi Iriyama, Satoshi Hashino, Satoshi Morita, Kazuteru Ohashi, Hina Takano, Shinya Kimura, Hisashi Sakamaki, Koiti Inokuchi, Chiaki Nakaseko, Masayuki Hino, Michihiro Uchiyama
Publikováno v:
Internal Medicine
Objective The aim of this study was to prospectively investigate the efficacy and safety profiles of low-dose dasatinib therapy (50 mg once daily). Methods Patients with chronic myeloid leukemia in the chronic phase (CML-CP) who were being treated wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1bd0f73599e4a1dbb15110a7331975fa
https://doi.org/10.2169/internalmedicine.9035-17
https://doi.org/10.2169/internalmedicine.9035-17